Medline Homecare Beds: FDA Class I Correction for Fire and Entrapment Risks
Medline Industries has issued a critical safety correction involving multiple models of homecare beds following reports of overheating components, electrical hazards, and patient entrapment following reports of overheating components, electrical hazards, and patient entrapment, as detailed in an FDA safety communication.
The U.S. FDA has classified this action as a Class I recall, FDA’s highest risk classification. This indicates that continued use without following updated instructions may result in serious injury or death.
What Is the Issue?
The correction centers on electrical safety risks associated with the bed’s hand control pendant and wiring, which in certain conditions may overheat, melt, spark, cause electrical shock, or catch fire.
These risks are heightened when the bed is operated above its weight limit, movement is obstructed, or motors or components are jammed.
Medline has received reports of burning, smoking, and fire events linked to these issues.
Additional Risk: Patient Entrapment
A secondary but equally serious concern involves patient entrapment, particularly when non-Medline accessories are used. Improper accessories or misuse of the control pendant may result in unintended bed movement, potentially causing entrapment between the bed and rail/accessory, asphyxiation, serious injury, or death.
This risk is especially pronounced in homecare environments, where monitoring may be limited.
Affected Devices
The correction applies to several Medline Basic and Medlite homecare beds, including semi-electric and full-electric models, low-profile variants, and multi-unit packaged configurations (All associated with specific SKUs and UDI-DIs listed in the FDA notice).
Reported Adverse Events
As of December 18, 2025, there were 12 injuries and one death associated with electrical hazards, and two injuries and one death associated with entrapment incidents.
Required Actions for Users
Medline and the FDA recommend the following immediate actions.
Electrical Safety. Keep beds unplugged when not actively adjusting position. Immediately unplug the bed and service if the pendant becomes hot, wiring is damaged, or smoke or sparking occurs.
Safe Operation. For safe operation of the bed, do not exceed weight limits, ensure there are no obstructions to movement, and avoid jammed or stalled components.
Pendant Handling. Do not store the pendant on the mattress. Hang the pendant on the bed frame when not in use.
Accessories. Use only Medline-approved accessories and side rails, and do not use extension cords or third-party components.
Manufacturer Contact Information
Customers with questions or adverse events should contact Medline Industries by phone at 866-359-1704, or by email (recalls@medline.com).
MDP Analysis
This event highlights several critical regulatory and quality system considerations, including electrical safety, risk management, post-market surveillance, human factors and home use risk, and compatibility of accessories that are used with or integrated into the device.
Electrical Safety and IEC 60601 Alignment
The failure mode, overheating and fire risk, points directly to electrical safety and fault condition control, core elements of IEC 60601 compliance.
Risk Management (ISO 14971)
The scenario reflects inadequate control of reasonably foreseeable misuse (e.g., overloading, obstruction) and potential gaps in hazard identification and mitigation.
Post-Market Surveillance
The identification of multiple injuries and deaths demonstrates the importance of complaint trending and the role of real-world data in detecting systemic issues.
Human Factors and Home Use Risk
Homecare environments have reduced supervision and an increased variability in use. Because of this, there is a higher reliance on clear instructions and safe design.
Accessory Compatibility and System Integration
Entrapment risk underscores a recurring issue of a system-level safety breakdown when components are mixed outside intended configurations.
Bottom Line
This correction reinforces a fundamental principle that medical device safety is not just about design; it also depends on real-world use conditions, user behavior, and system integration.
Manufacturers must anticipate not only intended use, but also consider the potential risks of misuse, environmental variability, and third-party interactions with the device.
Links
Read the FDA’s announcement here.
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...
